In the fourth quarter alone, revenue reached $9.2 million, marking a 1% increase year-over-year, although it was down 8% on a constant currency basis. The gross margin for Q4 expanded to 74%, up from 70% in Q4 2024. The company also reported a net loss of $5.5 million for the quarter, compared to a loss of $7.6 million in the same period last year.
CytoSorbents highlighted several strategic initiatives aimed at enhancing its operational efficiency and financial stability. The company successfully secured an additional $2.5 million from an amended credit facility in November 2025, which has improved its balance sheet flexibility. Furthermore, a strategic workforce and cost reduction program was implemented in Q4 2025, resulting in a 10% reduction in headcount, aimed at achieving cash flow breakeven in the second half of 2026.
The company is also actively engaging with the FDA regarding its DrugSorb-ATR device, which is designed to reduce serious perioperative bleeding in patients treated with blood thinners. Following a formal appeal meeting with the FDA in July 2025, the agency confirmed there were no safety concerns regarding the device, although additional information was requested to support the proposed label indication. CytoSorbents plans to submit a new De Novo application incorporating real-world data from its international STAR Registry.
Overall, while CytoSorbents has made progress in its financial performance and strategic initiatives, the company continues to face challenges in achieving profitability. The management remains optimistic about the future, focusing on driving growth across all sales channels and advancing regulatory approvals for its innovative products.
